Medexus Drug Patent Portfolio
Medexus owns 1 orange book drug protected by 1 US patent Given below is the list of Medexus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8664231 | Concentrated methotrexate solutions | 01 Jun, 2029 | Active |
Latest Legal Activities on Medexus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Medexus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Aug, 2021 | US8664231 (Litigated) |
| Review Certificate Mailed | 03 Sep, 2019 | US8664231 (Litigated) |
| Review Certificate | 13 Aug, 2019 | US8664231 (Litigated) |
| Termination or Final Written Decision | 07 Feb, 2018 | US8664231 (Litigated) |
|
Request for Trial Granted
Critical
| 08 Feb, 2017 | US8664231 (Litigated) |
| Termination or Final Written Decision | 08 Dec, 2016 | US8664231 (Litigated) |
| Request for Trial Granted in Part | 01 Sep, 2016 | US8664231 (Litigated) |
| Petition Requesting Trial | 20 Jul, 2016 | US8664231 (Litigated) |
| Petition Requesting Trial | 22 Feb, 2016 | US8664231 (Litigated) |
| Termination or Final Written Decision | 30 Apr, 2015 | US8664231 (Litigated) |
|
Request for Trial Granted
Critical
| 06 Jan, 2015 | US8664231 (Litigated) |
| Petition Requesting Trial | 10 Jul, 2014 | US8664231 (Litigated) |
|
Recordation of Patent Grant Mailed
Critical
| 04 Mar, 2014 | US8664231 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Mar, 2014 | US8664231 (Litigated) |
|
Issue Notification Mailed
Critical
| 12 Feb, 2014 | US8664231 (Litigated) |
Medexus's Drug Patent Litigations
Medexus's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 01, 2014, against patent number US8664231. The petitioner Antares Pharma, Inc., challenged the validity of this patent, with Medac Gesellschaft Fur Klinische as the respondent. Click below to track the latest information on how companies are challenging Medexus's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8664231 | July, 2016 |
FWD Entered
(07 Feb, 2018)
| MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH | Koios Pharmaceuticals LLC |
| US8664231 | February, 2016 |
Terminated-Settled
(08 Dec, 2016)
| MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH | Frontier Therapeutics, LLC |
| US8664231 | July, 2014 |
Terminated-Settled
(30 Apr, 2015)
| Medac Gesellschaft Fur Klinische | Antares Pharma, Inc. |
Medexus Drug Patents' Oppositions Filed in EPO
Medexus drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 15, 2011, by Antares Pharma, Inc.. This opposition was filed on patent number EP07786239A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP07786239A | Oct, 2012 | Actavis Group ehf | Opposition rejected |
| EP07786239A | Sep, 2011 | Antares Pharma, Inc. | Opposition rejected |
Medexus's Family Patents
Medexus Drug List
Given below is the complete list of Medexus's drugs and the patents protecting them.
1. Rasuvo
Rasuvo is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8664231 | Concentrated methotrexate solutions |
01 Jun, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rasuvo's drug page